» Articles » PMID: 37075801

Clinical Characteristics of Post-COVID-19 Persistent Cough in the Omicron Era

Overview
Date 2023 Apr 19
PMID 37075801
Authors
Affiliations
Soon will be listed here.
Abstract

Cough is one of the most common symptoms of acute coronavirus disease 2019, but cough may persist for weeks or months. This study aimed to examine the clinical characteristics of patients with post-coronavirus disease (COVID) persistent cough in the Omicron era. We conducted a pooled analysis comparing 3 different groups: 1) a prospective cohort of post-COVID cough (> 3 weeks; n = 55), 2) a retrospective cohort of post-COVID cough (> 3 weeks; n = 66), and 3) a prospective cohort of non-COVID chronic cough (CC) (> 8 weeks; n = 100). Cough and health status was assessed using patient-reported outcomes (PROs). Outcomes, including PROs and systemic symptoms, were longitudinally evaluated in the prospective post-COVID cough registry participants receiving usual care. A total of 121 patients with post-COVID cough and 100 with non-COVID CC were studied. Baseline cough-specific PRO scores did not significantly differ between post-COVID cough and non-COVID CC groups. There were no significant differences in chest imaging abnormality or lung function between groups. However, the proportions of patients with fractional exhaled nitric oxide (FeNO) ≥ 25 ppb were 44.7% in those with post-COVID cough and 22.7% in those with non-COVID CC, which were significantly different. In longitudinal assessment of the post-COVID registry (n = 43), cough-specific PROs, such as cough severity or Leicester Cough Questionnaire (LCQ) scores, significantly improved between visits 1 and 2 (visit interval: median 35 [interquartile range, IQR: 23-58] days). In the LCQ score, 83.3% of the patients showed improvement (change ≥ +1.3), but 7.1% had worsened (≤ -1.3). The number of systemic symptoms was median 4 (IQR: 2-7) at visit 1 but decreased to median 2 (IQR: 0-4) at visit 2. In summary, post-COVID persistent cough was similar in overall clinical characteristics to CC. Current cough guideline-based approaches may be effective in most patients with post-COVID cough. Measurement of FeNO levels may also be useful for cough management.

Citing Articles

Clinical characteristics and effects of inhaled corticosteroid in patients with post-COVID-19 chronic cough during the Omicron variant outbreak.

Xie P, Zhang Y, Niu W, Tu B, Yang N, Fang Y BMC Pulm Med. 2024; 24(1):156.

PMID: 38539172 PMC: 10967081. DOI: 10.1186/s12890-024-02937-7.


The Course of COVID-19 and Long COVID: Identifying Risk Factors among Patients Suffering from the Disease before and during the Omicron-Dominant Period.

Babicki M, Kolat D, Kaluzinska-Kolat Z, Kapusta J, Mastalerz-Migas A, Jankowski P Pathogens. 2024; 13(3).

PMID: 38535610 PMC: 10975347. DOI: 10.3390/pathogens13030267.


Updated Clinical Practice Guidelines for the Diagnosis and Management of Long COVID.

Seo J, Kim S, Kim Y, Kim E, Kim T, Kim T Infect Chemother. 2024; 56(1):122-157.

PMID: 38527781 PMC: 10990882. DOI: 10.3947/ic.2024.0024.

References
1.
Ambrosino P, Accardo M, Mosella M, Papa A, Fuschillo S, Spedicato G . Performance of fractional exhaled nitric oxide in predicting response to inhaled corticosteroids in chronic cough: a meta-analysis. Ann Med. 2021; 53(1):1659-1672. PMC: 8451665. DOI: 10.1080/07853890.2021.1979242. View

2.
Kang Y, Oh J, Lee J, Small P, Chung K, Song W . Long-COVID severe refractory cough: discussion of a case with 6-week longitudinal cough characterization. Asia Pac Allergy. 2022; 12(2):e19. PMC: 9066079. DOI: 10.5415/apallergy.2022.12.e19. View

3.
Elfessi Z, Steadman B, Rubinstein I . Fractional Exhaled Nitric Oxide in Normoxic Adult Patients With COVID-19 Infection in the Emergency Department: A Preliminary Observation. J Clin Med Res. 2022; 14(7):291-292. PMC: 9365665. DOI: 10.14740/jocmr4755. View

4.
Grant M, Geoghegan L, Arbyn M, Mohammed Z, McGuinness L, Clarke E . The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS-CoV-2; COVID-19): A systematic review and meta-analysis of 148 studies from 9 countries. PLoS One. 2020; 15(6):e0234765. PMC: 7310678. DOI: 10.1371/journal.pone.0234765. View

5.
Maniscalco M, Ambrosino P, Poto R, Fuschillo S, Poto S, Matera M . Can FeNO be a biomarker in the post-COVID-19 patients monitoring?. Respir Med. 2022; 193:106745. PMC: 8789557. DOI: 10.1016/j.rmed.2022.106745. View